Ocular and Orbital Complications of Intraarterial Cisplatin A Case Report

Ocular and Orbital Complications of Intraarterial Cisplatin A Case Report

Despite advances in neurosurgery, radiation oncology, and chemotherapy, the prognosis for glioblastoma multiforme remains poor, with a median survival time of 11–12 months. Cisplatin (cis-diamminedichlorideplatinum II) is one treatment for glioblastoma multiforme. Higher response rates have been ach...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-ophthalmology Vol. 17; no. 3; pp. 195 - 198
Main Authors: Wu, Helen M, Lee, Andrew G, Lehane, Daniel E, Chi, T Linda, Lewis, Richard Alan
Format: Journal Article
Language:English
Published: Hagerstown, MD Williams & Wilkins 01-09-1997
Lippincott Williams & Wilkins
Subjects:
Adult
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Biological and medical sciences
Brain Neoplasms - drug therapy
Cisplatin - administration & dosage
Cisplatin - adverse effects
Drug toxicity and drugs side effects treatment
Eye Diseases - chemically induced
Fatal Outcome
Female
Fluorescein Angiography
Fundus Oculi
Glioblastoma - drug therapy
Humans
Infusions, Intra-Arterial
Medical sciences
Ophthalmoplegia - chemically induced
Optic Atrophy - chemically induced
Orbital Diseases - chemically induced
Pharmacology. Drug treatments
Pupil Disorders - chemically induced
Toxicity: eye
Antineoplastic agent
Human
Intracranial
Nervous system diseases
Internal carotid
Retinopathy
Toxicity
Orbit(eye) disease
Malignant tumor
Glioblastoma multiforme
Cisplatin
Case study
Malignant glioma
Chemotherapy
Eye disease
Treatment
Central nervous system disease
Intraarterial administration
Platinum II Complexes
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite advances in neurosurgery, radiation oncology, and chemotherapy, the prognosis for glioblastoma multiforme remains poor, with a median survival time of 11–12 months. Cisplatin (cis-diamminedichlorideplatinum II) is one treatment for glioblastoma multiforme. Higher response rates have been achieved by intraarterial (IA) infusion than by systemic infusion of this agent. Cisplatin therapy may cause neurologic complications, and IA delivery has been reported to cause ocular toxicity. We report a patient who experienced intraorbital and intraocular toxicity following supraophthalmic IA injection of cisplatin.
ISSN:1070-8022
1536-5166
DOI:10.1097/00041327-199709000-00010